Researchers from DZNE and Otto von Guericke University Magdeburg have identified individuals with increased risk for dementia ...

A first-of-its-kind study will use ultrasound and light therapies to investigate targeted treatment of Alzheimer’s disease, dementia and Parkinson’s disease. The new study by scientists at Nottingham ...

However, there is a lack of research into the safety and effectiveness of melatonin for people with dementia, and experts may not recommend it as a treatment due to an increased risk of falls.

As a person's dementia progresses, their dental needs may become more complicated. The person might need specialist treatment and mental capacity to consent to treatment may need to be assessed.

The health service advises: "A diagnosis helps people with dementia get the right treatment and support. It can also help ...

The Drug Discovery programme is Alzheimer's Society's innovative approach to dementia treatment development. The result of which means new, better treatments could be available in half the time of a ...

Patients who are evaluated through the ADMDC should expect to have their options for treatment identified and explained to them so that they may make a well informed decision about their care. If a ...

Scientists think these plaques are toxic to brain cells and that clearing them using drugs would be a massive advance in dementia treatment, although not a cure. There haven't been any new ...

This could potentially reduce treatment costs and the number of required infusions. Psychotic episodes -- like hallucinations or delusions -- related to dementia can be scary for all involved.

The mother of an eight-year-old boy with a rare disease has spoken of her pride at seeing him complete Ironkids Wales with a ...

The impotence pill Viagra may be a useful treatment against Alzheimer's disease ... some of the proteins that accumulate in this type of dementia. The Cleveland team also analysed a database ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...